Motilal Oswal
    NIFTY 50
Motilal Oswal

Eisai Pharma to bet on tiered pricing in India

Updated : April 20, 2018 07:06 PM IST

The portfolio, which is currently marketed by Biogen and UCB, had sales of around Rs 55 crore in FY17.
Eisai expects this portfolio to grow at 10% CAGR and said it will start contributing a third to the company’s revenues in the next three years.
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more

You May Also Like

Live TV